386 filings
Page 14 of 20
6-K
pxhc6 l057ta
11 Dec 19
Annual and Special General Meeting of Shareholders
4:38pm
424B5
of5u2t3
5 Dec 19
Prospectus supplement for primary offering
5:29pm
6-K
hhxbpzkfrs85ujm
4 Dec 19
Therapix Biosciences Announces Pricing of $1,250,000 Registered Direct Offering
9:26am
6-K
96eaam 4op8lqu8q2
3 Dec 19
Current report (foreign)
12:00am
6-K
nevtvt0tfcu u8m6p
26 Nov 19
Report of Foreign Private Issuer
4:01pm
6-K
4kl0p
19 Nov 19
Report of Foreign Private Issuer
8:33am
6-K
ixcyji1 q1ha6b
13 Nov 19
Therapix Biosciences Announces Positive Topline Results From Phase IIa Clinical Trial of THX-110 for Obstructive Sleep Apnea Program
4:07pm
6-K
3dtfzbjg0ps
7 Nov 19
Therapix Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger
5:22pm
6-K
qtpibtpchrp sck4
15 Oct 19
Therapix Biosciences Announces Positive Data From Recent Pre-Clinical Study for New Drug Candidate THX-210
4:10pm
6-K
kmh 3q7ku
11 Oct 19
Current Report of Foreign Issuer
12:00am
EFFECT
krp8e61 demr5xlty5l9
6 Sep 19
Notice of effectiveness
12:15am
CORRESP
xrmd9ln m8wivvnkvfq5
3 Sep 19
Correspondence with SEC
12:00am
F-3/A
u4d5zmm5ijy6oglijwo
29 Aug 19
Shelf registration (foreign) (amended)
4:49pm
CORRESP
zudqs
29 Aug 19
Correspondence with SEC
12:00am
6-K
mhgv1b8xu
27 Aug 19
Current report (foreign)
4:13pm
UPLOAD
55e1p qz98
26 Aug 19
Letter from SEC
12:00am
F-3
68wxt
22 Aug 19
Shelf registration (foreign)
5:25pm
6-K
2aeoi65 b2wjbj5
31 Jul 19
Therapix Biosciences Announces Canadian Product LicenseĀ Issuance for TheraPEA (CannAmideā¢), a Non-Opiate Based Pain Management Supplement
4:03pm
6-K
crjjtsewnch
23 Jul 19
Therapix Biosciences Signs LOI to Merge With Destiny Biosciences Global Corp. in a
4:05pm
6-K
mlqa1cl
5 Jul 19
Therapix Biosciences Announces First Quarter 2019 Condensed Financial Data
6:08am